Last updated 8 days ago
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
500 patients around the world
Available in Argentina, Brazil
AbbVie
14Research sites
500Patients around the world
This study is for people with
Non-Hodgkin Lymphoma
Follicular lymphoma
Lymphoma
Non-Hodgkin lymphoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Av. Galvan 4102, CABA, Buenos Aireswww.cemic.edu.ar/
J. E. Uriburu 1450, CABA, Buenos Aireshttps://www.fundaleu.org/
R. Maestro Cardim, 637 - Bela Vista, São Paulo - SP, 01323-001
Av. República do Líbano, 611 - Ibirapuera, São Paulo - SP, 04501-000
Rua Pedro de Toledo, 1800 - Vila Clementino, São Paulo - SP, 04039-000
Rua Dr. Ovídio Pires de Campos 785 - Estado de São Paulo 05403-000
R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900
Av. Prof. Montenegro - Jardim Sao Jose, Botucatu - SP, 18618, Brazil
R. Doná Silvéria, 150 - Chácara Braz Miraglia, Jaú - SP, 17210-080, Brazil
R. Prof. Antônio Prudente, 212 - Liberdade, São Paulo - SP, 01509-010
StudyEPCORE FL-1
SponsorAbbVie
Study typeInterventional
Conditions
Follicular lymphomaNon-Hodgkin lymphoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05409066
